Judged by one (admittedly imperfect) metric, Facebook’s $19 billion acquisition wasn’t as outrageous as it might appear.
Mike OrcuttFollow @twitterapi
I’m MIT Technology Review’s research editor. I spend my days taking things extremely seriously and attempting with all my nerdy might to piece together bigger pictures from the bits and shreds of truth I manage to filter from the information barrage. I’m particularly obsessed with the energy-related challenges facing humanity and the future of the Internet.
Mike Orcutt's Stories
Though still volatile, Bitcoin is surging in value and being spent more freely; it's also inspired a legion of competitors.
Microparticles that block the body’s immune response to damaged tissue could help prevent further harm.
The ability to print retinal cells could lead to new therapies for retinal disorders such as macular degeneration.
A novel vaccine design could lead to new weapons against often deadly bacterial infections.
Coal could be a source of cheap, nontoxic fluorescent nanoparticles useful for biomedicine.
A material that selectively blocks heat and light could finally make it practical to add smart windows to buildings.
A layer-by-layer fabrication tool lets researchers quickly form complicated biological tissue in three-dimensional space.
The 2013 Global Innovation Index looks very similar to last year’s, but its ranking of the most efficient innovators features several new names.
Researchers are designing a “dialysis-like” machine that could identify and remove pathogens responsible for an often lethal blood infection.